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Inﬂammation and signaling pathwaysIn the last decades some reports reveal the neuropeptide neurotensin (NT) as an immune mediator in the
Central Nervous System and in the gastrointestinal tract, however its effects on skin immunity were not
identiﬁed. The present study investigates the effect of NT on signal transduction and on pro/anti-
inﬂammatory function of skin dendritic cells. Furthermore, we investigated how neurotensin can modulate
the inﬂammatory responses triggered by LPS in skin dendritic cells. We observed that fetal-skin dendritic cells
(FSDCs) constitutively express NTR1 and NTR3 (neurotensin receptors) and that LPS treatment induces
neurotensin expression. In addition, NT downregulated the activation of the inﬂammatory signaling pathways
NF-κB and JNK, as well as, the expression of the cytokines IL-6, TNF-α, IL-10 and the vascular endothelial
growth factor (VEGF), while the survival pathway ERK and epidermal growth factor (EGF) were upregulated.
Simultaneous dendritic cells exposure to LPS and NT induced a similar cytokine proﬁle to that one induced by
NT alone. However, cells pre-treated with NT and then incubated with LPS, completely changed their cytokine
proﬁle, upregulating the cytokines tested, without changes on growth factor expression. Overall, our results
could open new perspectives in the design of new therapies for skin diseases, like diabetic wound healing,
where neuropeptide exposure seems to be beneﬁcial.ptide; (CNS), Central Nervous
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Wound healing (WH) is a complex and well organized process
involving different cells and mediators, which perfectly communicate
to ensure that the inﬂammatory phase, important in the elimination
of pathogens, does not culminate into infection. This process has
received much attention by the scientiﬁc community since innumer-
ous wound healing diseases have become critical or even impossible
to cure. Atopic dermatitis, psoriasis and diabetic wound healing are
examples of serious cutaneous diseases. It is therefore imperative to
understand the molecular and cellular mechanisms of the disease in
order to uncover better therapies. WH involves different cells, namelykeratinocytes, ﬁbroblasts, endothelial cells, Langerhans cells (LCs),
macrophages, mastocytes and platelets, diverse inﬂammatory medi-
ators, such as growth factors, chemokines and cytokines, and it also
requires complex biological and molecular events that induce cell
migration, cell proliferation and extracellular matrix deposition
(ECM) [1]. Neuropeptides play an imperative role in wound healing,
being key modulators of the inﬂammatory phase of WH. Neuropep-
tides can be produced by skin cells or released by sensory neurons
when responding to stimuli, promoting different cellular responses
[2]. Substance P, Calcitonin Gene Related Peptide (CGRP), Vasoactive
intestinal peptide (VIP), Secretin, Secretoneurin and stressor neuro-
peptides induce migration and maturation of LCs, similar to
lipopolysaccharide (LPS), a Toll-like receptor (TLR)4 agonist that has
long been used as a potent inducer of dendritic cell (DC) maturation
[3]. However, CGRP, VIP, Pituitary adenylate cyclase-activating
peptide (PACAP) and α-Melanocyte-stimulating hormone (MSH)
mediate an anti-inﬂammatory response and promote a Th2 cytokine
polarizing proﬁle in LCs. Previous studies have identiﬁed neurotensin
(NT)-positive ﬁbers and NT expression in the skin, suggesting
important cutaneous functions [4,5]. Furthermore, the presence of
NT in the skin has been implicated in the pathogenesis of skin
disorders exacerbated by stress [6]. However, the role of NT in LCs and
skin inﬂammation has not been explored so far. In the nervous
system, NT has a pro-inﬂammatory role, inducing vasodilatation,
Table 1
Primer sequences for targeted cDNAs.
Primer 5′-3′sequence (F:forward; R:reverse) RefSeqID
HPRT1 F: GTTGAAGATATAATTGACACTG NM_013556
R: GGCATATCCAACAACAAAC
NT F: AATGTTTGCAGCCTCATAAATAAC NM_024435
R:TGCCAACAAGGTCGTCATC
NTR1 F: GGCAATTCCTCAGAATCCATCC NM_018766
R: ATACAGCGGTCACCAGCAC
NTR2 F: GCCATTACTAACAGTCTAAGC NM_008747
R: GCAATTCGTCCTATTCTACAC
NTR3 F: ATGGCACAACTTCCTTCTG NM_019972
R: AGAGACTTGGAGTAGACAATG
IL-1β F: ACCTGTCCTGTGTAATGAAAG NM_008361
R: GCTTGTGCTCTGCTTGTG
IL-6 F: TTCCATCCAGTTGCCTTC NM_031168
R: TTCTCATTTCCACGATTTCC
IL-10 F: CCCTTTGCTATGGTGTCCTTTC NM_010548
R: ATCTCCCTGGTTTCTCTTCCC
TNF-α F: CAAGGGACTAGCCAGGAG NM_013693
R: TGCCTCTTCTGCCAGTTC
IFN-δ F: CTTCTTGGATATCTGGAGGAACTG NM_008337
R: GGTGTGATTCAATGACGCTTATG
G-CSF F: TCATTCTCTCCACTTCCG NM_009971
R: CTTGGTATTTACCCATCTCC
CCL5 F: CACTCCCTGCTGCTTTGC NM_013653
R: CACTTGGCGGTTCCTTCG
VEGF-A F: CTT GTT CAG AGC GGA GAA AGC NM_001025250
R: ACA TCT GCA AGT ACG TTC GTT
EGF F: GCA CAG TTT GTC TTC AAT GGC NM_010113
R: TGT TGG CTA TCC AAA TCG CCT TGC
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directional migration and phagocytosis of neutrophils [7,8]. In the
gastrointestinal tract, NT is involved in the physiopathology of colonic
inﬂammation, a tissue rich in neurotensin receptor 1 [9], stimulating
NF-κB dependent Interleukin (IL)-8 secretion and IL-8 gene expres-
sion in human colonocyte cells [10]. In a recent report NT treatment
induces an anti-inﬂammatory cytokine proﬁle in colitis, characterized
by the decrease of IL-6 and Tumor necrosis factor (TNF)-α expression
[11].
Neurotensin is a tridecapeptide that binds to neurotensin re-
ceptors: neurotensin receptor 1, 2 and 3 (NTR1, NTR2 and NTR3).
NTR1 and NTR2 are G protein-coupled receptors while NTR3 is an
intracellular receptor with a single transmembrane domain, which is
100% homologous to gp95/sortilin [12]. NTR1, rather than NTR2,
exhibits high afﬁnity for NT [13] and NT effects on the Central Nervous
System (CNS) are essentially mediated by this receptor, as NTR3 is
predominantly localized in the trans Golgi network, although the
mature protein can also be present in the plasma membrane [14].
Neurotensin receptors mediate the activation of different signaling
pathways. NTR1 induces intracellular signaling through Phospholi-
pase C and the inositol phosphate signaling pathways. It also functions
through the production of cGMP, cAMP and arachidonic acid, through
the MAP kinase pathways and inducing the inhibition of Akt activity
[15].
This work attempted to address the role of NT in skin dendritic
cells in the absence and presence of an inﬂammatory stimulus,
focusing on signal transduction, inﬂammatory mediators and pro/
anti-inﬂammatory function of LCs. The knowledge of the molecular
and cellular mechanisms of neuropeptides in the skin and its
application on skin wounds could discern new therapeutic ap-
proaches for skin pathologies.
2. Materials and methods
2.1. Materials
Lipopolysaccharide (LPS) from Escherichia coli (serotype 026:B6),
an activator of inﬂammation, was obtained from Sigma Chemical Co.
(St. Louis, MO, USA), NT was obtained from Bachem (Weil am Rhein,
Germany) and NTR1 inhibitor SR48692 was obtained from Axon
Medchem (Groningen, The Netherland). The protease inhibitor
cocktail (Complete Mini) and the phosphatase inhibitor cocktail
(PhosSTOP) were obtained from Roche (Carnaxide, Portugal).
Bicinchoninic acid (BCA) kit assay was obtained from Novagen. 30%
Acrylamide/BisSolution 29:1 (3.3% c), TEMED and SYBR green were
obtained from BioRAD, and High Capacity cDNA Reverse Transcription
kit was obtained from Applied Byosistems.
The polyvinylidene diﬂuoride (PVDF) membranes and the anti-
body against b-actin were purchased from Millipore Corporation
(Bedford, MA). The antibodies against phopho-(p-)AKT/PKB (Thr
308) and NTR were purchased from Santa Cruz (Frilabo), the
antibodies against total JNK were obtained from UpState (Tape
Group), the antibodies against p-JNK, p-ERK, p-p38 MAPK and total
AKT/PKBwere purchased from Cell Signaling and the antibody against
total p38 MAPK was purchased from Biolegend (Tape Group). The
alkaline phosphatase-linked secondary antibodies (anti-mouse and
anti-rabbit) and the enhanced chemiﬂuorescence (ECF) reagent were
obtained from GE Healthcare (Carnaxide, Portugal). The Vectashield
mounting medium was purchased from Vector, Inc. (Burlingame, CA,
USA) and the Alexa Fluor 555 phalloidin antibodywas purchased from
Invitrogen (Barcelona, Spain).
TRIzol® was obtained from Invitrogen, diethyl pyrocarbonate
(DEPC) was acquired from AppliChem. Methanol, ethanol, and
isopropanol were obtained from Merck. All primers were obtained
from MWG Biotech (Ebersberg, Germany). All other reagents were
purchased from Sigma Chemical Co.2.2. Culture of FSDC
The fetal skin dendritic cell line (FSDC), Langerhans cell analogs
from mice, was kindly supplied by Dr. G. Girolomoni (Department of
Biomedical and Surgical Science, Section of Dermatology and
Venereology, University of Verona, Italy). This cell line is a skin DC
precursor with antigen presenting capacity. This cell line was
previously characterized [16] and the phenotype was conﬁrmed in
our lab [17]. FSDC was cultured in serum-containing endotoxin-free
Iscove's Modiﬁed Dulbecco's Medium (IMDM) supplemented with
10% (v/v) of inactivated fetal calf serum, 3.02 g/l sodium bicarbonate,
100 U/ml penicillin, 100 g/ml streptomycin and 30 mMof glucose, in a
humidiﬁed incubator with 5% CO2/95% air, at 37 °C. Along the
experiments, cells were monitored by microscopic observation in
order to detect any morphological changes.
2.3. MTT assay
Cells were stimulated with 1 μg/ml of LPS and treated with 10 and
100 nM of NT, for 24 h. Cell viability was determined by the reduction
of MTT (Mosmann T., 1983), as previously described [17]. LPS or/and
NT stock solutions were added to obtain the different ﬁnal in-well
concentrations studied.
2.4. Immunocytochemistry
Immunocytochemistry was performed as described previously by
us [18]. Fluorescence labeling was visualized using a ﬂuorescence
microscope – Zeiss Axiovert 200 – and images captured with a
coupled AxioCamHR camera. The ﬁlter set used included an excitation
ﬁlter of 560 nm and an emission ﬁlter of 575 nm for Alexa Fluor 555
and an emission ﬁlter of 420 nm for DAPI.
2.5. Western blot
Cells (7.5×105) were plated in 12-well plates and treated with
10 nM of NT, or/and 1 μg of LPS, during 5, 15, 30 and 60 min. After
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sonication buffer containing 50 mM Tris HCl pH 8, 150 mM NaCl, 1%
NP-40 (Nonidet P-40), 0.5% Sodium Deoxycholate, 0.1% SDS, 2 mM
EDTA, protease inhibitor cocktail, phosphatase inhibitor cocktail and
DTT 1 mM. Cell lysates and protein quantiﬁcation were performed as
previously described [18].
The levels of IκB-α, p-ERK1/ERK2, p-p38 MAPK, p-SAPK/JNK and
p-AKT/PKB protein levels were evaluated by western blots. Proteins
were separated by electrophoresis on a 10% (v/v) sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS–PAGE), and transferred
to polyvinylidene ﬂuoride (PVDF) membrane, as previously described
[18]. The immune complexes were detected by membrane exposure to
the ECF reagent, followed by scanning for blue excited ﬂuorescence on
the VersaDoc (Bio-Rad Laboratories, Amadora, Portugal). Membranes
were stripped and reprobedwith antibodies against total ERK1/2, SAPK/
JNK, p38 MAPK and AKT/PKB, or with an antibody for b-actin. The
generated signals were analyzed using the Image-Quant TL software.2.6. RNA extraction
Cells (2×106) were plated in 6-well plates in a ﬁnal volume of 6 ml
and treated with 1 μg/ml of LPS and/or 10 nM of NT during 6 h, or pre-Fig. 1. FSDC viability. Cells were plated in 48/24-well plates, maintained in IMDMmedium (c
LPS simultaneously, for 24 h, at 37 °C, with 5% CO2. (A)MTT assay. After incubations, theMTT
in experimental procedures. Student's t-test was used relative to control. Each value rep
morphology. After incubation, cells were stained as described in experimental procedures
captured with a coupled AxioCamHR camera (400×). Image a is representative of the nuclea
some LPS treated cells and image d of LPS and NT treated cells, not observed in a and b.treated with 10 nM of NT during 24 h and stimulated with 1 μg/ml of
LPS during 6 h, or left untreated (control). Total RNA was isolated
from these cells with the TRIzol® reagent according to the manufac-
turer's instructions. The RNA concentration was determined by
OD260 measurement using a Nanodrop spectrophotometer (Wil-
mington, DE, USA). RNA was stored in RNA Storage Solution (Ambion,
Foster City, CA, USA) at −80 °C.2.7. Real time RT-PCR
One microgram of total RNA was reverse transcribed using High
Capacity cDNA Reverse Transcription (RT), from Applied Biosystems,
according to the manufacturer's instructions. After the cDNA
synthesis, the samples were diluted with RNase-free water up to a
volume of 100 μl and concentration of 0.01 μg/μl. Real-time RT-PCR
was performed as previously described [18]. The results were
normalized using a reference gene, hypoxanthine phosphoribosyl-
transferase 1 (HPRT-1) which was previously validated in our lab for
FSDC [18]. Primers were designed using Beacon Designer® Software
v7.2, from Premier Biosoft International and thoroughly tested
(Table 1). Quantitative RT-PCR results were analyzed as in Neves
et al. [18].ontrol), incubated with 10, 50 and 100 nM of NT, 1 μg/ml of LPS alone, and with NT and
solution (5 mg/ml) was added to each well and cell viability was evaluated as described
resents the mean±SD from 3 experiments, performed in duplicate. (B) FSDC nuclei
. Images were acquired using a ﬂuorescence microscope – Zeiss Axiovert 200 – and
r morphology of control cells and b of NT treated cells; image c represent the nuclei of
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The results are presented as mean±S.D., and the means were
statistically compared using the unpaired two-tailed Student's t-test,
using Graphpad software. The signiﬁcance level was *pb0.05,
**pb0.01, and ***pb0.001.
3. Results
3.1. Effect of neurotensin on FSDC viability
Cell viability was evaluated by the MTT assay which measures the
metabolic activity of the cells, as well as through the examination of
nuclei morphology after cell treatment for 24 h with 10, 50 or 100 nM
of neurotensin alone or in the presence of LPS. As indicated in Fig. 1A,
NT treatment did not signiﬁcantly affect cell viability when compared
with non-treated cells. The higher cell viability, however not
signiﬁcant, observed in cells treated with LPS and 100 nM of NT
may be a response to the inﬂammatory stimulus of LPS, as cells modify
their metabolic activity to express different inﬂammatory molecules
like cytokines, chemokines and growth factors, to act in inﬂammation.
Nuclei morphology was assessed by DNA staining with DAPI and NT
treated cells did not change nuclei morphology in comparison to the
control (Fig. 1B — a and b), although cells treated with LPS or LPS and
NT displayed some apoptotic nuclei (Fig. 1B — c and d).
3.2. Cell morphology
FSDC morphology was analyzed by ﬂuorescence microscopy in
order to evaluate actin and nuclei staining (Fig. 2). In control
conditions and NT treated cells, cells showed actin arrangements
dispersed through the entire cell, but with sutured actin ﬁlaments inFig. 2. Cytoskeleton and nuclei morphology of FSDC. Cells were immunostained with Alexa F
Images A and B represent cells in control conditions and C represents neurotensin treated c
cells. Immunostaining was performed as described in “Materials and methods”. The imag
magniﬁcation.the periphery of the cytoplasm, evidencing numerous vesicles related
to the high endocytic activity of these immature cells. Some cells also
showed dendritic-like projections (Fig. 2A, B and C). On the other
hand, when cells were stimulated with LPS or LPS and NT for 24 h, the
actin in the periphery of the cytoplasm was more sutured in some
regions than in others and the actin cortical network appeared to be
disassembled, probably demonstrating FSDC adjustments for migra-
tion. Some dendritic-like projections were also seen in LPS or LPS and
NT stimulated cells (Fig. 2D, E and F). Indeed, NT alone did not
promote FSDC adjustment for migration.
3.3. NTR expression in FSDC
Protein expression of neurotensin receptors was determined in
untreated cells (control), byWestern Blot analysis. OnlyNTR1 andNTR3
were constitutively expressed in FSDC, where NTR3 seems to be the
most expressed receptor among the NTRs (Fig. 3A). Furthermore, NTR
gene expression was also assessed by real-time RT-PCR in untreated
cells (control) and cells exposed to LPS for 6 h. Comparing the relative
amounts of the transcripts, NTR3 was the most abundant among the
analyzed NTR receptors, as shown in Fig. 3B, in accordance to the WB
results. The treatment of cells with LPS for 6 h caused a decrease in
transcription of all NTRs, by −1.14±0.55 (n=3), −1.88±0.77
(*pb0.05, n=3) and −0.85±0.78 (n=3) fold, for NTR1, NTR2 and
NTR3 respectively, while expression of NTwas increased by 3.75±0.50
(***pb0.0001, n=3) relative to control (Fig. 3C).
3.4. Intracellular signaling pathways modulated by NT in FSDC
To evaluate the intracellular pathways stimulated by NT in skin
dendritic cells, Western blot analysis was performed to detect the
activated/phosphorylated forms of MAP kinases (ERK1/ERK2, SAPK/luor 555 phalloidin (red) antibody for actin and stained with DAPI (blue) for the nuclei.
ells; D and E are representative of LPS treated cells and F represents LPS and NT treated
es were acquired by ﬂuorescence microscopy and photographs were taken at 400×
Fig. 3. Neurotensin receptors (NTRs) expression in FSDC. Cells were maintained in IMDMmedium (control) or treated with 1 μg/ml of LPS, at 37 °C, with 5% CO2. (A) After 30 min of
incubation, cell extracts were subjected to WB analysis using NTR1, NTR2 and NTR3 antibodies, with normalization to b-actin. The blot shown is representative of 3 independent
experiments yielding similar results (B/C). After 6 h of incubation, total RNA was isolated and retrotranscribed as indicated in experimental procedures. The mRNA levels were
assessed by quantitative real-time RT-PCR. Gene expression is indicated as genes studied/10,000 molecules of the reference gene HPRT1 (3B) or mean log2 values of fold changes
relative to the control (C). Each value represents the mean±S.D. from three independent experiments (*pb0.05; ***pb0.001 unpaired two-tailed Student's t-test).
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NF-κB was also evaluated. For that, FSDC was incubated, during short
time periods, with 10 nM of NT. In these conditions we observed that
NT upregulated IκB-α levels (Fig. 4A), although no alterations were
observed for the MAP kinases (data not shown). The NF-κB inhibitory
protein – IκBα – was not degraded and its expression increased in a
time-dependent manner until 30 min, indicating an inhibition of the
NF-κB signaling pathways (Fig. 4A).
FSDC was also stimulated with LPS being a maximal phosphory-
lation for ERK1/ERK2, SAPK/JNK, p38 MAPK and AKT/PKB observed
between 15 and 30 min, with a more notorious effect on the ERK1/ERK2 signaling pathway (Fig. 4B). The expression of IκBα decreased in
a time-dependent manner until the 30 min time point, indicating
activation of the NF-κB (Fig. 4B). We next tested the ability of NT to
modulate LPS-triggered intracellular signals. When NT was added
simultaneously with LPS, p38 MAPK and ERK1/ERK2 activation was
upregulated essentially at 30 min, while the SAPK/JNK signaling
pathway was downregulated at 30 min, when compared with the
results obtained with LPS alone (Fig. 4B). Between 5 and 15 min, NT
also caused an increase in the expression of IκBα, diminishing NF-κB
activation (Fig. 4B). No alterations were observed in the AKT/PKB
signaling pathway (data not shown). Furthermore, in the presence of
Fig. 4. Activation of intracellular signaling pathways by NT and LPS in FSDC. Cells were
maintained in culture medium (control), or incubated with 10 nM of NT alone (A) or
simultaneouslywith LPS (B) for 5, 15, 30 or 60 min. Total cell extracts were subjected toWB
analysis, as described in "Materials and methods", using antibodies to p-ERK1/2, p-JNK1/2
andp-p38MAPK. The activation of NF-κBwas evaluatedby the determination of the levels of
its inhibitory protein, IkB-α (band on the bottom). Equal loading was evaluated with
antibodies to total ERK1/2, SAPK/JNK and p38 MAPK, or with an anti-β-actin antibody. The
blots shown are representative of at least three independent experiments yielding similar
results. ThequantiﬁcationofWBbandswasevaluatedwithnormalization toERK1/2, JNK1/2,
p38MAPK and IkB-α antibodies. Each value represents mean±SD (t-student test,
comparing treatments and stimulus of the same time set).
Table 2
Expression of cytokines, chemokines and growth factors triggered by LPS in FSDC.
Gene LPS
(mean log2 values of fold changes relative to the control)
IL-1β 4.94±3.18 (***pb0.001, n=14)
IL-6 8.00±3.22 (***pb0.001, n=17)
TNF-α 3.58±1.17 (***pb0.001, n=16)
IFN-γ 0.72±1.34 (n=4)
G-CSF 6.65±3.13 (**pb0.01, n=5)
CCL5 7.52±2.44 (***pb0.001, n=16)
IL-10 2.28±2.29 (***pb0.001, n=17)
EGF −0.35±1.26 (n=16)
VEGF −0.15±1.38 (n=16)
PDGF 0.73±0.74 (**pb0.01, n=10)
Cells were plated in 6-well microplates in culture medium and treated with 1 μg of LPS
during 6 h, at 37 °C, with 5% CO2. Total RNA was isolated and retrotranscribed as
indicated in experimental procedures. The mRNA levels were assessed by quantitative
real-time RT-PCR. Gene expression is indicated as mean log2 values of fold changes
relative to the control. Values represent the mean±S.D. from at least three
independent experiments (**pb0.01; ***pb0.001 unpaired two-tailed t-student test
relative to the corresponding control).
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described signaling pathways returned to normal (data not shown),
suggesting that the observed effects occurred through NTR1 receptor.
3.5. Modulation of gene expression by neurotensin
To evaluate the effects of LPS on FSDC gene expression after 6 h of
incubation, IL-1β, TNF-α, Interferon (IFN)-γ, Granulocyte colony-
stimulating factor (G-CSF), the chemokine CCL5, IL-10, Epidermal
growth factor (EGF), Vascular endothelial growth factor (VEGF) and
Platelet-derived growth factor (PDGF) were measured, as shown in
Table 2. LPS highly induced the expression of the pro-inﬂammatory
cytokines TNF-α, IL-1β, IL-6 and G-CSF, as well as, the chemokineCCL5. We observed that the anti-inﬂammatory cytokine IL-10 was
slightly induced, while growth factors were almost unaffected
(Table 2). To further evaluate the effect of NT on key inﬂammatory
cytokines and chemokines, cells were subjected to different NT and
LPS incubation protocols to mimic different physiopathological
conditions that occur in vivo. Cells were treated with 10 nM of NT
alone for 6 h or 30 h; incubated with LPS alone or simultaneously with
10 nM of NT and LPS for 6 h, and ﬁnally incubated with 10 nM of NT
for 24 h before an additional stimulus of LPS for 6 h. Pre-treatment of
FSDC with NT simulated in vivo treatments with NT immediately
after skin injury (before inﬂammation starts). Simultaneous cell
treatmentwith LPS and NT for 6 h simulated a treatmentwith NT after
injury where inﬂammation is present. Total RNA was isolated from
cells, quantiﬁed and reverse transcribed to cDNA, to perform real-time
RT-PCR.
After 6 h of FSDC exposure to neurotensin, the expression of the
majority of the cytokines diminished, namely IL-6, TNF-α and IL-10, by
−0.34±0.26 (n=3),−1.10±0.62 (*pb0.05, n=3) and−1.77±0.91
(*pb0.05, n=3) fold, relative to control (Fig. 5A). In addition,when cells
were exposed to NT for long-time periods (30 h), the observed effects
were similar but with smaller intensity. The expression of CCL5 was
signiﬁcantly increased by 0.74±0.50 (*pb0.05, n=4) fold, relative to
control (Fig. 5A).
In cells incubated simultaneously with LPS and 10 nM of NT for 6 h,
the cytokine proﬁle was similar to the proﬁle induced by NT alone, as
shown in Fig. 5B. In addition, we observed a tendency for a decrease in
IL-6 and TNF-α expression by−0.57±1.21 (n=4) and−0.97±0.89
(n=3) fold and a tendency for an increase in CCL5 by 0.54±1.37
(n=3) fold, relative to control, while the expression of IL-10 was
unaltered (Fig. 5B). In contrast, when cells were pre-treated with
10 nM of NT during 24 h and then incubated with LPS for 6 h, the
cytokine proﬁle changed. We observed an upregulation of the
expression of all cytokines, with a clear tendency in the upregulation
of IL-6 expression by 0.70±1.66 (n=6), relative to control (Fig. 5B).
Concerning growth factors expression, after 30 h of NT incubation,
EGF was increased by 1.45±1.18 (*pb0.05, n=4) fold, while the
expression of VEGF decreased by −0.29±0.18 (*pb0.05, n=4) fold,
relative to control (Fig. 5A). When cells were simultaneously treated
with NT and LPS for 6 h, the expression of EGF increased by 2.37±2.20
(*pb0.05, n=3) fold, relative to control, while VEGF expression was
unaltered (Fig. 5B). However, growth factors expression did not change
when cells were pre-treated with 10 nM of NT during 24 h and then
incubatedwith LPS for 6 h, as shown in Fig. 5B.Moreover, todetermine if
the increased expression of EGF observed had an autocrine or paracrine
effect on these cells, the expression of the EGF receptor by FSDC, as well
as its phosphorylation by NT and/or LPS was determined by real time
Fig. 5.Modulation of gene expression by neurotensin and LPS in FSDC. Cells were maintained in IMDMmedium (control) and treated with 10 nM of NT during 6 h (white bars), 30 h
(black bars) (A), or simultaneously treated with 1 μg/ml of LPS and 10 nM of NT for 6 h (white bars), pre-treated with 10 nM of NT during 24 h and then incubated with LPS for 6 h
(black bars) (B), at 37 °C, with 5% CO2. Total RNAwas isolated and retrotranscribed as indicated in "Materials andmethods". ThemRNA levels were assessed by quantitative real-time
RT-PCR. Gene expression is indicated as mean log2 values of fold changes relative to the control. Each value represents the mean±S.D. from at least three independent experiments
(*pb0.05, unpaired two-tailed Student's t-test relative to the corresponding control).
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receptor nor the receptor was phosphorylated (data not shown),
suggesting a possible paracrine function of this growth factor in other
skin cells under these conditions.
4. Discussion
Neurotensin has been largely studied in the CNS, although poorly
studied in the skin. In this work we demonstrated that skin dendritic
cells express neurotensin receptors, namely NTR1 and NTR3, which
were downregulated in inﬂammatory conditions. On the other hand,
neurotensin was only produced in these cells under inﬂammatory
conditions, suggesting that neurotensin expressed by FSDC may be
important to other skin cells, exerting paracrine functions.
The activation of signaling pathways and gene expression was
determined in the absence and in the presence of the inﬂammatory
stimulus of LPS. LPS is a glycolipid component of the outer wall
membrane of Gram-negative bacteria that has long been used as apotent inducer of DC maturation. It acts trough the toll-like receptor 4
(TLR4), triggering MyD88 and TRIF pathways that results in the
phosphorylation of various intracellular kinases, including the IκB
kinase (IKK), the ERK1/2, p38 MAPK and JNK1/2, implicated in the
synthesis of inﬂammatory mediators, like some cytokines, chemo-
kines and growth factors.
In this work we observed that neurotensin alone or under
inﬂammatory conditions downregulated the activation of the signal-
ing pathway NF-κB which is involved in diverse immune responses
mediated by cells, increasing gene transcription of chemokines,
cytokines, adhesion molecules, enzymes that produce secondary
inﬂammatorymediators and inhibitors of apoptosis [19]. The observed
downregulated expression of the pro-inﬂammatory cytokines IL-6 and
TNF-α might have been caused by the decrease observed in NF-κB
activation, since the expression of these genes is strongly dependent of
this transcription factor [18]. In addition to NF-κB, the inﬂammatory
signaling pathway JNK was also downregulated by NT under
inﬂammatory conditions. The anti-inﬂammatory cytokine IL-10 was
1870 L. da Silva et al. / Biochimica et Biophysica Acta 1813 (2011) 1863–1871decreased by NT alone, suggesting that NT downregulated not only
inﬂammatory cytokines, but also anti-inﬂammatory cytokines, de-
creasing the immunologic capacity of dendritic cells. On the other
hand, the p38 MAPK signaling pathway was upregulated by neuro-
tensin, being probably involved in the observed CCL5 increase, as
described previously [18].
ERK can directly phosphorylate many transcription factors
involved in the expression of important genes involved in cell cycle
progression, like platelet-derived growth factor and heparin-binding
epidermal growth factor (HB-EGF), in apoptosis prevention and in
cytokine expression [20]. Therefore, the NT-induced increase of EGF
expression observed in FSDC may be related to ERK activation by
neurotensin. EGF may have a paracrine effect in other cells other than
FSDC, promoting epidermal growth and keratinocyte proliferation,
differentiation and migration, promoting epidermal thickness, im-
portant in the last phases of WH [21]. Furthermore, EGF treatment of
the wound accelerates wound healing [22]. On the other hand, VEGF-
A was decreased by NT at short-time incubation periods. VEGF is an
important regulator of endothelial cell proliferation, migration and
cell survival, inducing vascular hyperpermeability and angiogenesis,
as well as, inducingmonocyte/macrophage recruitment [23]. All these
processes are involved in the ﬁrst phases of WH but are irrelevant in
the last phases of WH. Moreover, the most important results reported
will be conﬁrmed in human LC, isolated and differentiated from
peripheral blood monocytes in the presence of IL-4, GM-CSF and TGF-
beta, as previously reported by us [17].
Similar effects have been described for different neuropeptides in
the skin. In fact, these effects seem to be enhanced when more than
one neuropeptide act in the skin, evidencing a synergistic effect of
some neuropeptides. For instance, CGRP and Substance P act together
to increase blood ﬂow, being potent and long lasting microvascular
dilators in the surrounding of the site of injury, as well as α-MSH
and ACTH peptides interact with MC receptors on melanocytes,
keratinocytes, and Langerhans cells to modify their functional activity,
to increase cutaneous melanin pigmentation and generate local anti-
inﬂammatory and immunosuppressive effects [24,25]. Knowing
the effect of neurotensin in the skin, its effects could be enhanced
when acting together with other immunosuppressive neuropeptides,
like α-MSH and ACTH. Moreover, NT effects in monocytes and PMN
have not been determined to date, which along with dendritic cells
play amajor role in the inﬂammatory phase ofWH. The effect of NT on
monocytes and PMNmay accurately clarify the possible NT function in
the inﬂammatory phase of WH.
Translating these results obtained in skin dendritic cells to events
occurring in vivo during wound healing we can hypothesize that if NT
is released in the beginning of the inﬂammatory processes, it may
induce pathological effects, diminishing the capacity of cells to
respond to inﬂammation and probably promoting infections; how-
ever, if NT is released in the middle or at the end of the inﬂammatory
phase, as well as, in the migration-remodeling phases of WH, NT may
modulate de degree of inﬂammation, end inﬂammation and induce
the progression to migration-remodeling phases of WH, promoting
wound healing through EGF production.
In vitro pre-treatment (24 h) of cells with NT mimicked an
exogenous and in vivo pre inﬂammatory treatment with NT. In this
case, NT enhanced the inﬂammatory response evoked by LPS,
probably provoked by the cumulative effects of LPS and NT. Indeed,
this pro-inﬂammatory proﬁle in FSDC may be important in the ﬁrst
phases of WH. Correlating these in vitro studies with those events
occurring in vivo, if NT is applied immediately after injury in the
wounds, previously to the start of the inﬂammatory process, NT can in
fact upregulate the immune function of cells in the inﬂammatory
phase of WH, being promissory in the treatment of normal WH. On
the other hand, if NT is applied in the wounds after injury, when the
inﬂammatory process has already started (in vitro cell stimulation
with LPS and NT during 6 h), NT can negatively modulate the cells'immune responses. In these circumstances, delayed wounds known
to have higher levels of NT, could possibly be treated with antibodies
for NT that will decrease the NT concentration in the wounds,
promoting WH. Moreover, once NT levels are determined in skin
pathologies and if NT is then defective, a treatment with low doses of
NT may promote WH. Further similar studies should be performed
both in other skin cells and in in vivo conditions, in order to disclose
the potential beneﬁc therapeutic role of NT on skin pathological
conditions.
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